We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-0.32%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$970M
AUM Growth
-$417M
Cap. Flow
-$194M
Cap. Flow %
-20.04%
Top 10 Hldgs %
49.08%
Holding
83
New
26
Increased
6
Reduced
23
Closed
17

Top Buys

Rank Stock Value
1
RPTX
Repare Therapeutics
RPTX
+$39.6M
2
VTYX
Ventyx Biosciences
VTYX
+$34.6M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$23.2M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$21.3M
5
ALGS icon
Aligos Therapeutics
ALGS
+$16.8M

Top Sells

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$62.9M
2
PMVP icon
PMV Pharmaceuticals
PMVP
+$41.7M
3
NKTX icon
Nkarta
NKTX
+$35.5M
4
CMPS
Compass Pathways
CMPS
+$35M
5
BCYC
Bicycle Therapeutics
BCYC
+$33.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PYXS icon
51
Pyxis Oncology
PYXS
$184M
$3.14M 0.32%
+286,652
New +$3.28M
TVTX icon
52
Travere Therapeutics
TVTX
$5.2B
$3.1M 0.32%
+100,000
New +$2.82M
NUVL
53
DELISTED
Nuvalent
NUVL
$2.56M 0.26%
134,650
– –
LIAN
54
DELISTED
LianBio American Depositary Shares
LIAN
$2.54M 0.26%
+412,837
New +$4.72M
WVE icon
55
Wave Life Sciences
WVE
$1.13B
$2.51M 0.26%
+800,000
New +$3.32M
SLGC
56
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$2.33M 0.24%
200,493
– –
BMEA icon
57
Biomea Fusion
BMEA
$90.4M
$1.88M 0.19%
252,320
-450,000
-64% -$4.76M
MRNS
58
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.54M 0.16%
+130,000
New +$1.5M
VERA icon
59
Vera Therapeutics
VERA
$2.39B
$1.34M 0.14%
+50,000
New +$1.11M
COGT icon
60
Cogent Biosciences
COGT
$6.95B
$1.29M 0.13%
150,000
-775,000
-84% -$6.74M
OMGA
61
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$999K 0.1%
88,235
– –
VRNA
62
DELISTED
Verona Pharma
VRNA
$820K 0.08%
+122,000
New +$623K
DAWN
63
DELISTED
Day One Biopharmaceuticals
DAWN
$624K 0.06%
37,069
-15,000
-29% -$308K
IVVD icon
64
Invivyd
IVVD
$175M
$508K 0.05%
+70,000
New +$1.82M
NUVB.WS
65
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$126K 0.01%
66,666
– –
MREO
66
Mereo BioPharma
MREO
$49.4M
$75K 0.01%
46,984
– –
ALT icon
67
Altimmune
ALT
$581M
– –
-700,000
Closed -$7.92M
GHRS icon
68
GH Research
GHRS
$1.92B
– –
-324,333
Closed -$6.44M
GLUE icon
69
Monte Rosa Therapeutics
GLUE
$1.86B
– –
-50,000
Closed -$1.11M
IOVA icon
70
Iovance Biotherapeutics
IOVA
$2.1B
– –
-500,000
Closed -$12.3M
KROS icon
71
Keros Therapeutics
KROS
$199M
– –
-15,000
Closed -$593K
NKTX icon
72
Nkarta
NKTX
$159M
– –
-1,275,777
Closed -$35.5M
PASG icon
73
Passage Bio
PASG
$14.7M
– –
-6,251
Closed -$1.25M
PMVP icon
74
PMV Pharmaceuticals
PMVP
$58.7M
– –
-1,400,000
Closed -$41.7M
PRLD icon
75
Prelude Therapeutics
PRLD
$370M
– –
-400,000
Closed -$12.5M
1 2
3
4

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q4 2021 Portfolio in Review

As of Q4 2021, Logos Global Management held 83 positions worth $970M, down 30% from $1.39B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Logos Global Management withdrew a net $194M in Q4 2021, closing 17 positions and reducing 23 holdings. Its most notable exit was Deciphera Pharmaceuticals, Inc. Common Stock, an estimated $62.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Ventyx Biosciences worth $36.2M.

  • Logos Global Management's largest Q4 2021 buy was Ventyx Biosciences: 1,824,280 shares worth $36.2M.
  • Logos Global Management added most to Repare Therapeutics in Q4 2021, an estimated $39.6M increase.
  • Logos Global Management's biggest Q4 2021 reduction was Compass Pathways, cutting an estimated $35M.
  • Logos Global Management fully exited Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2021, selling an estimated $62.9M.
  • Logos Global Management's ten largest holdings make up 49% of its $970M portfolio in Q4 2021.
  • Logos Global Management opened 26 new positions and closed 17 in Q4 2021.
  • Logos Global Management's portfolio value fell 30% quarter-over-quarter to $970M.

Based on Logos Global Management's 13F filing for Q4 2021, filed 14 Feb 2022.